Westfield, NJ, United States of America

Christopher Nielsen


Average Co-Inventor Count = 7.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2004-2006

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Christopher Nielsen: Innovator in Pharmaceutical Chemistry

Introduction

Christopher Nielsen is a notable inventor based in Westfield, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as inhibitors and antagonists. With a total of 3 patents to his name, Nielsen's work has the potential to impact various therapeutic areas.

Latest Patents

Nielsen's latest patents include innovative processes that are crucial for drug development. One of his patents focuses on the "Synthesis of quinoline 5-carboxamides useful for the preparation of PDE IV inhibitors." This patent discloses a process for making specific compounds that can be utilized in treating various conditions. Another significant patent is for the "Synthesis of piperidine and piperazine compounds as CCR5 antagonists." This invention outlines novel processes to prepare compounds that may play a role in addressing certain diseases.

Career Highlights

Christopher Nielsen is currently employed at Schering Corporation, where he continues to advance his research and development efforts. His work at the company has allowed him to collaborate with other talented professionals in the field, further enhancing the impact of his inventions.

Collaborations

Nielsen has worked alongside notable colleagues such as Suhan Tang and William W. Leong. These collaborations have contributed to the successful development of his patented inventions and have fostered a productive research environment.

Conclusion

Christopher Nielsen is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable patents that may influence future therapeutic developments. His contributions reflect a commitment to innovation and collaboration in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…